Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis.
In a preliminary 123I-IBZM SPECT study in first-episode psychosis, a relationship between striatal dopaminergic D2 receptor (D2R) binding and premorbid adjustment was suggested. These results were replicated in the present study (n = 18), and D2R binding at diagnosis predicted a high probability for schizophrenia outcome by 2-year follow-up. The present findings contribute to the evidence of abnormal D2R binding in schizophrenia and suggest that SPECT might be useful for outcome prediction in first-episode psychosis.
Corripio
Iluminada
I
Department of Psychiatry, Hospital de la Sta Creu I Sant PauC, Universidad Autónoma de Barcelona (UAB) [corrected] Sant Antoni Maria Claret, 16708025 Barcelona, Spain. icorripio@hsp.santpau.es
Pérez
Víctor
V
Catafau
Ana M
AM
Mena
Esther
E
Carrió
Ignasi
I
Alvarez
Enric
E
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001549:Benzamides; D015415:Biomarkers; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D017072:Neostriatum / Q000000981:diagnostic imaging / Q000378:metabolism*; D011379:Prognosis; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D011618:Psychotic Disorders / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism*; D011759:Pyrrolidines; D019275:Radiopharmaceuticals; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome
D014150:Antipsychotic Agents; D001549:Benzamides; D015415:Biomarkers; D011759:Pyrrolidines; D019275:Radiopharmaceuticals; D017448:Receptors, Dopamine D2; C055743:3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide